150 related articles for article (PubMed ID: 38032636)
21. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
[TBL] [Abstract][Full Text] [Related]
22. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma.
Díez-Alonso M; Mendoza-Moreno F; Gómez-Sanz R; Matías-García B; Ovejero-Merino E; Molina R; Soto-Schütte S; San Juan A; Gutierrez-Calvo A
Int J Surg Oncol; 2021; 2021():3946875. PubMed ID: 34557315
[TBL] [Abstract][Full Text] [Related]
24. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
26. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.
Zhou SL; Xin HY; Sun RQ; Zhou ZJ; Hu ZQ; Luo CB; Wang PC; Li J; Fan J; Zhou J
JAMA Surg; 2022 Jan; 157(1):59-65. PubMed ID: 34730772
[TBL] [Abstract][Full Text] [Related]
27. GATA binding protein 2 overexpression is associated with poor prognosis in KRAS mutant colorectal cancer.
Xu K; Wang J; Gao J; Di J; Jiang B; Chen L; Wang Z; Wang A; Wu F; Wu W; Shen L; Su X
Oncol Rep; 2016 Sep; 36(3):1672-8. PubMed ID: 27460045
[TBL] [Abstract][Full Text] [Related]
28. EARLY-ONSET COLORECTAL CANCER: AN ELEVEN-YEAR ANALYSIS OF CLINICOPATHOLOGICAL CHARACTERISTICS AT A TERTIARY HEALTHCARE CENTER.
Piñerúa-Gonsálvez JF; Zambrano-Infantino RDC; Rizzo-Rodríguez MA; Dueñas-Diez A; Fernández-Salazar L
Arq Gastroenterol; 2023; 60(3):315-321. PubMed ID: 37792760
[TBL] [Abstract][Full Text] [Related]
29. Treatment patterns and survival differ between early-onset and late-onset colorectal cancer patients: the patient outcomes to advance learning network.
Burnett-Hartman AN; Powers JD; Chubak J; Corley DA; Ghai NR; McMullen CK; Pawloski PA; Sterrett AT; Feigelson HS
Cancer Causes Control; 2019 Jul; 30(7):747-755. PubMed ID: 31102084
[TBL] [Abstract][Full Text] [Related]
30. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
[TBL] [Abstract][Full Text] [Related]
31. Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Am J Gastroenterol; 2012 May; 107(5):782-9. PubMed ID: 22349355
[TBL] [Abstract][Full Text] [Related]
32. Impact of primary colorectal Cancer location on the KRAS status and its prognostic value.
Xie MZ; Li JL; Cai ZM; Li KZ; Hu BL
BMC Gastroenterol; 2019 Mar; 19(1):46. PubMed ID: 30917791
[TBL] [Abstract][Full Text] [Related]
33. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
34. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
35. Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women.
Limburg PJ; Limsui D; Vierkant RA; Tillmans LS; Wang AH; Lynch CF; Anderson KE; French AJ; Haile RW; Harnack LJ; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR
Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):681-4. PubMed ID: 22337533
[TBL] [Abstract][Full Text] [Related]
36. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
[TBL] [Abstract][Full Text] [Related]
37. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
[TBL] [Abstract][Full Text] [Related]
38. KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location.
Tabuso M; Christian M; Kimani PK; Gopalakrishnan K; Arasaradnam RP
Pathol Oncol Res; 2020 Oct; 26(4):2537-2548. PubMed ID: 32594310
[TBL] [Abstract][Full Text] [Related]
39. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women.
Samadder NJ; Vierkant RA; Tillmans LS; Wang AH; Weisenberger DJ; Laird PW; Lynch CF; Anderson KE; French AJ; Haile RW; Potter JD; Slager SL; Smyrk TC; Thibodeau SN; Cerhan JR; Limburg PJ
Gastroenterology; 2013 Aug; 145(2):348-56.e1-2. PubMed ID: 23665275
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of colorectal cancer biomarkers and their impact on clinical outcomes in Riyadh, Saudi Arabia.
Alharbi A; Bin Dokhi H; Almuhaini G; Alomran F; Masuadi E; Alomran N
PLoS One; 2021; 16(5):e0249590. PubMed ID: 33979337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]